2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168134
    CDK-IN-15
    		Inhibitor
    CDK-IN-15 (Compound 456) is a potent Cyclin A inhibitor, with an IC50 of 0.14 μM.
    CDK-IN-15
  • HY-RS02375
    Cdk2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk2 Mouse Pre-designed siRNA Set A
    Cdk2 Mouse Pre-designed siRNA Set A
  • HY-151878
    CDK7-IN-20
    		Inhibitor
    CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research.
    CDK7-IN-20
  • HY-156643
    Tacaciclib
    		Inhibitor
    Tacaciclib is a CDK inhibitor, antineoplastic effect.
    Tacaciclib
  • HY-168896
    CDK9 autophagic degrader 1
    		Degrader
    CDK9 autophagic degrader 1 (Compound 28) is a ATTEC degrader that can be used to degrade CDK9 and also affects the levels of the associated Cyclin T1. CDK9 autophagic degrader 1 shows over 80% CDK9 inhibition rate at 100 nM. ( Pink: LC3B ligand (HY-168897); Black: linker (HY-W017758); Blue: target protein ligand (HY-10008); linker + target protein ligand (HY-168898))
    CDK9 autophagic degrader 1
  • HY-147717
    CDK8-IN-7
    		Inhibitor
    CDK8-IN-7 (compound 12) is a potent and selective cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 3.5 nM. CDK8-IN-7 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 5.9, 4.8, 5.4, 16.2, 12.5-25 µM, respectively. CDK8-IN-7 has the potential for the research of AML-cancer.
    CDK8-IN-7
  • HY-50767S1
    Palbociclib-d4 hydrochloride
    		Inhibitor
    Palbociclib-d4 (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
    Palbociclib-d<sub>4</sub> hydrochloride
  • HY-172899
    Carbonic anhydrase inhibitor 33
    		Inhibitor
    Carbonic anhydrase inhibitor 33 (11D) is a dual Inhibitor of CA (Carbonic anhydrase) IX/XII and CDK6, with Ki values of 19.7 nM and 26.1 nM for hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 33 (11D) induces G1 arrest and apoptosis. Carbonic anhydrase inhibitor 33 (11D) can be used in the research for NSCLC.
    Carbonic anhydrase inhibitor 33
  • HY-169048
    CDK2/4-IN-2
    		Inhibitor
    CDK2/4-IN-2 (compound 56) is a CDK2 and CDK4 dual inhibitor with IC50s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer.
    CDK2/4-IN-2
  • HY-12422C
    rel-(2S,3R)-Voruciclib
    		Inhibitor
    rel-(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor.
    rel-(2S,3R)-Voruciclib
  • HY-156705
    CDK7-IN-25
    		Inhibitor
    CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) that can be used in cancer research.
    CDK7-IN-25
  • HY-139651
    CDK2-IN-7
    		Inhibitor
    CDK2-IN-7 is a CDK2 inhibitor for researching cancer (IC50 < 50 nM).
    CDK2-IN-7
  • HY-164376
    CDK4/6-IN-21
    		Inhibitor
    CDK4/6-IN-21 (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity.
    CDK4/6-IN-21
  • HY-155177
    CDK9-IN-27
    		Inhibitor
    CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC50s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC50s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research.
    CDK9-IN-27
  • HY-155966
    CDK2-IN-19
    		Inhibitor
    CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors.
    CDK2-IN-19
  • HY-150572
    CDK2-IN-11
    		Inhibitor
    CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer.
    CDK2-IN-11
  • HY-150609
    SHP2/CDK4-IN-1
    		Inhibitor
    SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC50 values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research.
    SHP2/CDK4-IN-1
  • HY-139449
    CDK4/6-IN-5
    		Inhibitor
    CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with Kis of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. (from patent WO2019207463A1 example A93).
    CDK4/6-IN-5
  • HY-RS02381
    CDK4 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK4 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK4 Human Pre-designed siRNA Set A
    CDK4 Human Pre-designed siRNA Set A
  • HY-147527
    CDK8-IN-5
    		Inhibitor
    CDK8-IN-5 is a potent CDK8 inhibitor with an IC50 of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease.
    CDK8-IN-5
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.